Baxdrostat

Brand names: Baxfendy · Active ingredient: Baxdrostat

In short: BAXFENDY, in combination with other antihypertensive drugs, is indicated for the treatment of hypertension, to lower blood pressure in adults who are not adequately controlled on other agents. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and

Forms & strengthsBAXFENDY is available as film-coated tablets: •1 mg pink, biconvex, round, film-coated tablets with “BX” debossed on one side and “1” on the other side. …
LabelAstraZeneca Pharmaceuticals LP
Label updatedSep 18, 2026

What is Baxdrostat used for?

BAXFENDY, in combination with other antihypertensive drugs, is indicated for the treatment of hypertension, to lower blood pressure in adults who are not adequately controlled on other agents. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. There are no controlled trials demonstrating risk reduction of these events with BAXFENDY.

Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the American College of Cardiology/American Heart Association (ACC/AHA).

Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. …

Baxdrostat dosage

Consider the patient’s risk of hyperkalemia and hyponatremia before initiating BAXFENDY. Assess serum potassium and sodium before initiation of BAXFENDY and periodically thereafter. Correct serum potassium and sodium abnormalities prior to initiation of BAXFENDY .

The recommended dosage of BAXFENDY is 2 mg orally once daily.

For patients at increased risk of hyperkalemia or hyponatremia, the recommended dosage is 1 mg orally once daily .

Swallow tablets whole. Do not cut, crush, or chew tablets. BAXFENDY may be taken with or without food.

If a dose is missed, take the next dose at the usual time. Do not take a double dose on the same day.

How to take Baxdrostat — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Hyperkalemia and Hyponatremia

Inform patients that BAXFENDY can cause hyperkalemia and hyponatremia .

Advise patients of the importance of regular blood tests to monitor serum potassium and sodium. Instruct patients to contact their healthcare provider immediately if they experience symptoms that may be caused by hyponatremia such as unusual fatigue, dizziness, dyspnea, headache, or confusion.

Advise patients receiving BAXFENDY to consult with their healthcare provider about the use of potassium supplements or salt substitutes containing potassium .

Manufacturing Information

Distributed by: AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850

BAXFENDY is a registered trademark of the AstraZeneca group of companies.

©AstraZeneca 2026

Warnings & precautions

Do not take this medicine if: None.

BAXFENDY can cause hyperkalemia .

Assess serum potassium prior to initiation of BAXFENDY and monitor periodically during treatment. Correct serum potassium abnormalities prior to initiation of BAXFENDY . More frequent monitoring is recommended for patients at increased risk of hyperkalemia (e.g., patients ≥ 65 years of age, those with diabetes mellitus or chronic kidney disease, and those receiving concomitant medications that increase serum potassium) .

If hyperkalemia occurs, treat hyperkalemia and consider interrupting or discontinuing BAXFENDY. Consider more frequent monitoring of serum potassium in patients who restart BAXFENDY after experiencing hyperkalemia. Permanently discontinue BAXFENDY if clinically significant hyperkalemia recurs.

BAXFENDY can cause hyponatremia .

Assess serum sodium prior to initiation of BAXFENDY and monitor periodically during treatment. Correct serum sodium abnormalities prior to initiation of BAXFENDY . More frequent monitoring is recommended for patients with low baseline serum sodium concentrations and those at risk of hyponatremia, such as those receiving concomitant medications that may cause hyponatremia.

If clinically significant hyponatremia occurs, treat the hyponatremia and consider interrupting or discontinuing BAXFENDY. Consider more frequent monitoring of serum sodium in patients who restart BAXFENDY after experiencing hyponatremia. Permanently discontinue BAXFENDY if clinically significant hyponatremia recurs.

Baxdrostat side effects

The following clinically significant adverse reactions are also discussed elsewhere in the labeling:

•Hyperkalemia

•Hyponatremia

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of BAXFENDY was evaluated over 12 weeks using the randomized, double-blind, placebo-controlled periods from three clinical trials in patients with hypertension not adequately controlled on other antihypertensive medications. Three of these trials [BaxHTN (NCT06034743), BrigHTN (NCT04519658), Bax24 (NCT06168409)] evaluated BAXFENDY 2 mg as add-on treatment and two trials [BaxHTN, BrigHTN] evaluated BAXFENDY 1 mg as add-on treatment. These data reflect exposure of 441 patients to BAXFENDY 2 mg and 333 patients to BAXFENDY 1 mg, with a mean treatment duration of 80 days for both BAXFENDY 2 mg and 1 mg. Analyses in this section are based on the 12‑week periods in these three trials. Uncontrolled, long-term safety data from 192 patients exposed to BAXFENDY 1 mg or 2 mg for a mean of 293 days and 172 patients exposed to BAXFENDY 2 mg for a mean of 327 days, were consistent with the safety profile observed during the 12-week, randomized, double-blind, placebo-controlled periods.

Hyperkalemia was the most frequently reported adverse reaction to BAXFENDY in the three clinical trials . …

Drug interactions

Monitor serum potassium more frequently when BAXFENDY is used concomitantly with drugs that impair potassium excretion or increase serum potassium. Concomitant use may increase the risk of hyperkalemia .

Strong and Moderate CYP3A Inducers

Monitor the therapeutic effect of BAXFENDY more frequently when concomitantly used with strong or moderate CYP3A inducers.

Baxdrostat is a CYP3A substrate. Strong or moderate CYP3A inducers may decrease baxdrostat plasma concentration, which may reduce the efficacy of BAXFENDY.

About this medicine

Baxdrostat is an aldosterone synthase inhibitor. The chemical name of baxdrostat is N-[(8R)-4-(1-methyl-2-oxo-1,2,3,4-tetrahydro-6-quinolinyl)-5,6,7,8-tetrahydro-8-isoquinolinyl]propanamide. The molecular formula is C22H25N3O2 and the molecular weight is 363.45 g/mol. The structural formula is:

BAXFENDY is available as a film-coated tablet for oral administration, containing 1 mg or 2 mg of baxdrostat. The inactive ingredients in BAXFENDY are croscarmellose sodium, lactose anhydrous, magnesium stearate, and microcrystalline cellulose. The film coating contains the following inactive ingredients: polyethylene glycol 3350, polyvinyl alcohol, talc, and titanium dioxide, in addition to ferric oxide red (1 mg strength tablets) or ferric oxide yellow (2 mg strength tablets).

How it works: Baxdrostat is an inhibitor of human aldosterone synthase. Aldosterone contributes to hypertension by promoting the retention of sodium and water by the kidneys, which increases blood volume and, consequently, raises blood pressure. Aldosterone can cause vascular dysfunction, inflammation, and fibrosis.

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID b1fc1ee7-facc-4099-b3db-a4c1daeaa4be. Read the full official label on DailyMed.

Related medicines

Atorvastatin Amlodipine Lisinopril Losartan Metoprolol Rosuvastatin Simvastatin Spironolactone